MAPT and tauopathy: We find that PGRN reduction with tauopathy significantly impairs activity of β-glucocerebrosidase (GCase), a protein previously associated with synucleinopathy45,46, while increasing tau inclusions that are immunoreactive for GCase substrate glucosylceramide (GlcCer).